PT-141 (Bremelanotide) for Female Sexual Dysfunction: What Clinicians Actually Do

What PT-141 Actually Is and Why Clinicians Reach for It Off-Label

Bremelanotide (brand name Vyleesi) is a melanocortin receptor agonist that acts on the brain, not the genitals. This central mechanism sets it apart from every other sexual medicine option your clinician might consider. It was approved by the FDA in June 2019 specifically for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD).

Off-label use is a different story. Many women who present to sexual medicine practices don't fit neatly into the HSDD box. They may have female sexual interest/arousal disorder (FSIAD), situational low desire tied to the menopause transition, or arousal problems that persist despite adequate hormonal management. Clinicians who specialize in women's sexual health often extend bremelanotide to these presentations because the central mechanism makes physiological sense across multiple desire and arousal diagnoses.

The Melanocortin Mechanism in Plain Language

Bremelanotide binds primarily to melanocortin-4 (MC4) receptors in the hypothalamus and limbic system, regions that regulate sexual motivation and reward. Receptor activation increases dopaminergic activity in pathways linked to appetitive sexual behavior. In practical terms: it doesn't increase genital blood flow directly and it doesn't change estrogen levels. It nudges the brain toward sexual interest.

This matters for women because female sexual dysfunction is disproportionately driven by desire-phase problems rather than the arousal-phase problems that dominate male sexual medicine. A drug acting centrally on desire circuitry fits the female phenotype of sexual dysfunction better than a vasodilator ever could.

Why HSDD Under-Diagnosis Matters

HSDD affects an estimated 8 to 10 percent of women across reproductive years, making it the most common female sexual dysfunction. Despite that prevalence, it remains chronically under-diagnosed because clinicians rarely ask about desire, and women rarely volunteer the complaint. The off-label reach of bremelanotide is partly a downstream consequence of that diagnostic gap: by the time a woman reaches a sexual medicine specialist, her symptoms often span multiple DSM-5 categories that existed as separate diagnoses before the 2013 merger of HSDD and female sexual arousal disorder into FSIAD.

The Key Trial Data Clinicians Are Actually Using

The FDA approval rests on two Phase 3 randomized controlled trials, RECONNECT Studies 1 and 2, enrolling a total of 1,267 premenopausal women with HSDD. Participants self-administered 1.75 mg bremelanotide or placebo subcutaneously in the abdomen or thigh before anticipated sexual activity over 24 weeks.

The primary outcomes were change from baseline in the Female Sexual Function Index (FSFI) desire domain score and the Female Sexual Distress Scale Revised (FSDS-R) item 13, which specifically captures distress about low desire.

Key results from the RECONNECT pooled analysis:

• Women on bremelanotide gained a mean of 0.5 points on the FSFI desire domain versus 0.3 points for placebo (statistically significant at p < 0.001).
• FSDS-R item 13 showed a mean decrease of 0.8 points versus 0.5 for placebo.
• Nausea occurred in approximately 40 percent of bremelanotide recipients compared to 1 percent on placebo, making it the dominant tolerability concern.
• Transient increases in blood pressure (mean systolic rise of 1-2 mmHg, peak within 4 hours) were noted in the treatment arm.

An important limitation: the absolute effect sizes are modest. The FSFI desire domain uses a 1.2 to 6.0 scale, meaning the 0.5 point between-group difference is real but clinically small for an individual woman. Clinicians who frame this honestly with their patients report better adherence than those who position it as a dramatic solution.

What the Trials Did Not Study

The RECONNECT trials enrolled premenopausal women almost exclusively, with a mean participant age of approximately 38 years. Postmenopausal women, women on systemic estrogen therapy, women with FSIAD (rather than isolated HSDD), and women with comorbid arousal or orgasm dysfunction were largely excluded. Every application of bremelanotide outside those parameters is an extrapolation, and that needs to be said clearly.

Clinicians using it off-label in perimenopausal or postmenopausal women are drawing on the mechanistic rationale, not a direct evidence base.

How Clinicians Actually Prescribe It: Dosing and Practical Protocol

Sexual medicine clinicians who prescribe bremelanotide off-label have developed a working clinical framework that fills gaps left by the prescribing information. Here is what that looks like in practice.

Starting Dose and Titration

The FDA-approved dose is a fixed 1.75 mg subcutaneous injection. There is no formal titration schedule in the label. Off-label practice has diverged from this in two ways:

1. Some compounding-familiar clinicians start women with a 0.5 mg or 1.0 mg trial dose to assess nausea and blood pressure response before moving to 1.75 mg. This is not supported by label but is used to improve first-experience tolerability.
2. A small number of sexual medicine practices use compounded bremelanotide at sub-approval concentrations for women who cannot tolerate full-dose nausea. The FDA-approved Vyleesi autoinjector delivers 1.75 mg per dose; any other concentration requires compounding and is fully off-label.

The labeled maximum is one injection per 24-hour period and no more than one injection per sexual event. The prescribing information explicitly states that more than one dose in 24 hours has not been studied and is not recommended.

Injection Technique and Timing

Women inject into the abdomen or outer thigh 45 minutes before anticipated sexual activity. The Vyleesi autoinjector is designed for self-administration. Most clinicians provide a training injection at the first visit and send women home with the autoinjector device.

Onset is typically 45 to 60 minutes. Peak effect occurs at roughly 1 to 2 hours post-injection. Duration of any desire-enhancing effect extends for several hours, though the pharmacokinetic half-life of bremelanotide is approximately 2.7 hours.

Managing the Nausea Problem

Nausea is the single largest clinical obstacle. Clinicians who see high volumes of bremelanotide patients routinely pre-treat with ondansetron 4 mg orally 30 to 60 minutes before injection. This is off-label use of ondansetron but is widely practiced and is consistent with the general antiemetic evidence base. Some clinicians prefer ginger supplementation or a small, bland snack prior to injection for women with mild symptoms.

Blood pressure rises transiently. Women with cardiovascular disease or uncontrolled hypertension should not use bremelanotide: the FDA label carries a specific cardiovascular warning noting that blood pressure increases and heart rate may decrease within 4 to 12 hours of dosing. Clinicians typically check resting blood pressure at baseline before prescribing.

Life-Stage Considerations Across the Female Lifespan

Reproductive-Age Women (20s to Early 40s)

This is the only population with direct trial evidence. For a premenopausal woman with a formal HSDD diagnosis, bremelanotide is on-label and the most evidence-based pharmacological option after flibanserin. Clinicians often prefer it over flibanserin (Addyi) because it is used on demand rather than taken daily, it has no alcohol restriction, and women retain control over timing relative to sexual activity.

PCOS is worth naming explicitly here. Women with PCOS have higher rates of sexual dysfunction than the general population, with one meta-analysis reporting FSFI total scores significantly lower in women with PCOS compared to controls. Testosterone excess in PCOS does not protect against desire-phase dysfunction; the insulin resistance, mood effects, and body-image burden of PCOS can override androgen advantage. Bremelanotide's central mechanism is mechanistically plausible in this group, but there are no PCOS-specific trial data.

Perimenopause (Typically Mid-40s to Early 50s)

The perimenopausal transition is the period of greatest flux in female sexual function. Erratic estrogen, rising FSH, emerging genitourinary symptoms, and sleep disruption converge in ways that affect both desire and arousal. The Menopause Society (formerly NAMS) 2022 position statement on sexual health names HSDD as the most prevalent female sexual dysfunction in the menopausal transition and notes that pharmacological options are limited and often under-used.

Perimenopausal women were not the primary population in RECONNECT, so any use here is off-label. A clinician may combine bremelanotide with low-dose vaginal estrogen if genitourinary syndrome of menopause (GSM) is also present, since bremelanotide does not address vaginal atrophy or pain.

Postmenopause

Desire decline after menopause is partly hormonal and partly neurological. Estrogen withdrawal reduces dopaminergic tone in desire-relevant circuits, which is the same circuitry bremelanotide targets. The theoretical rationale for off-label use in postmenopausal women is reasonable, but clinicians should be transparent: postmenopausal women were excluded from key trials, and blood pressure effects in older women with higher baseline cardiovascular risk need careful individual assessment.

Women who have had hormone-sensitive cancers and cannot use systemic hormonal therapies represent a specific group where sexual medicine specialists sometimes consider bremelanotide because it carries no estrogenic activity. The Menopause Society and ACOG Committee Opinion 659 have addressed hormonal management in this group; bremelanotide does not fall under those restrictions.

Pregnancy, Lactation, and Contraception: What You Must Know

This section is required reading if you are of reproductive age or considering pregnancy.

Pregnancy: Contraindicated

Bremelanotide must not be used during pregnancy. Animal reproductive studies showed fetal harm at doses below the human therapeutic dose: increased post-implantation loss, reduced fetal weight, and delayed ossification were observed in rats. Human data are absent because pregnant women were excluded from all trials. The FDA label assigns a specific warning: discontinue bremelanotide when pregnancy is recognized.

If you are trying to conceive, stop bremelanotide before attempting conception. The half-life is approximately 2.7 hours, so the drug clears quickly, but given the lack of human embryo safety data, clinicians typically recommend discontinuation at least one full cycle before active conception attempts.

Lactation: Insufficient Data, Avoid

No human lactation pharmacokinetic studies exist. It is unknown whether bremelanotide or its metabolites pass into breast milk, or at what concentrations. Because of this data gap, most clinicians advise against bremelanotide use during breastfeeding. Women who are postpartum and experiencing low libido (a very common postpartum experience tied to prolactin, sleep deprivation, and estrogen suppression) are generally counseled on non-pharmacological approaches first, with bremelanotide deferred until after weaning.

Contraception Requirements

Women using bremelanotide who do not wish to become pregnant should use reliable contraception. No specific contraception requirement is mandated in the FDA label (unlike, for example, isotretinoin), but given the fetal harm signal in animal studies, this is clinical common sense. Bremelanotide does not appear to interact with hormonal contraceptives based on available pharmacokinetic data.

Who This Is Right For, and Who It Is Not

Women Most Likely to Benefit

• Premenopausal women with a formal HSDD diagnosis, distress-confirmed (FSDS-R > 11 is commonly used as a threshold), who prefer on-demand dosing over a daily pill.
• Women who tried flibanserin and stopped due to daily pill burden, dizziness, or alcohol restriction.
• Perimenopausal women with predominantly desire-phase complaints, after optimizing sleep, stress, and relationship context, where a clinician has documented off-label discussion and consent.
• Women with PCOS and documented sexual distress, understanding this is fully off-label with no PCOS-specific efficacy data.

Women Who Should Not Use It

• Pregnant women or those actively trying to conceive.
• Breastfeeding women (insufficient safety data).
• Women with uncontrolled or high-risk hypertension or established cardiovascular disease.
• Women whose primary dysfunction is genitourinary pain (dyspareunia, vulvodynia) rather than desire deficit. Bremelanotide will not address pelvic floor dysfunction or vaginal atrophy; those need targeted treatment first.
• Women taking medications that significantly affect blood pressure.
• Women whose low desire is fully explained by an untreated psychiatric condition, relationship conflict, or unmanaged thyroid disease. Bremelanotide is not a substitute for treating those underlying causes.

Comparing Bremelanotide to Flibanserin (Addyi): A Clinical Decision Framework

Both bremelanotide (Vyleesi) and flibanserin (Addyi) are FDA-approved for premenopausal HSDD. Flibanserin was approved in 2015 and must be taken daily at bedtime, with a black-box warning against alcohol use. Bremelanotide was approved in 2019 and is used on demand.

| Feature | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | Dosing schedule | On demand, pre-sex | Daily (nightly) | | Route | Subcutaneous injection | Oral tablet | | Alcohol restriction | None | Black-box warning | | Primary side effect | Nausea, flushing | Dizziness, somnolence | | REMS program | No | Yes (ADDYI REMS) | | Off-label use | Common | Less common | | Cost/access | Often self-pay | Often self-pay |

The choice between them comes down to patient preference and side-effect tolerance. Women who cannot commit to daily dosing, or who drink alcohol socially, typically do better with bremelanotide. Women who are injection-averse or whose nausea history makes injections impractical typically do better with flibanserin.

The Evidence Gap: What We Still Don't Know About Bremelanotide in Women

The RECONNECT trials represented a real advance in female sexual medicine, but their design left significant questions open.

As one sexual medicine clinician on the WomanRx editorial board put it: "We have approval-level data in a narrow band of premenopausal women, and we're making real-world decisions across a much wider spectrum of patients. The mechanism is sound, the safety profile is manageable, but I always tell my patients that we're extrapolating when we move outside the trial population."

Specifically, what is still missing:

• Long-term safety data beyond 52 weeks of use.
• Efficacy and cardiovascular safety data in postmenopausal women.
• Head-to-head trial data comparing bremelanotide to flibanserin in the same population.
• Data on bremelanotide in women with PCOS, endometriosis, or after oophorectomy.
• Data on whether combining bremelanotide with testosterone therapy adds benefit over either alone (some sexual medicine specialists use this combination off-label, particularly in postmenopausal women).
• Pharmacokinetic data during lactation.

Women have been historically under-represented in clinical trials, and the field of female sexual medicine in particular has operated for decades without adequate funding or regulatory attention. The approval of both bremelanotide and flibanserin reflects genuine progress, but the evidence base remains thinner than what exists for erectile dysfunction pharmacotherapy, which has been studied in tens of thousands of men across multiple drug classes and decades of post-marketing data.

Monitoring, Follow-Up, and When to Stop

Clinicians who prescribe bremelanotide typically schedule a follow-up visit at four to six weeks after first use. At that visit, the key questions are:

1. Did you notice any change in sexual desire or experience?
2. How was the nausea? Did the pre-treatment antiemetic help?
3. Did you check your blood pressure? (Some clinicians ask women to self-monitor BP at home on the first two or three injection days.)
4. Are you experiencing any skin changes at the injection site?

A hyperpigmentation signal appeared in the clinical trials: focal hyperpigmentation of the face, breasts, and gums occurred in 1 percent of women on bremelanotide versus none on placebo. Women with darker baseline skin tone should be counseled about this before starting. Hyperpigmentation resolved slowly after stopping the drug, but in some women it persisted for weeks to months.

If there is no benefit after six to eight exposures, most clinicians recommend discontinuing. The drug does not produce tolerance or dependence, and stopping is straightforward given its short half-life.